Monoclonal antibodies, specific for antigens expressed on lymphoid malignancies, which have been conjugated to toxins such as ricin, hold promise in the therapy of childhood leukemia and lymphoma. Anti-B4-blocked ricin (anti-B4-bR) is such an agent, and a phase I study of this agent was conducted in children with relapsed or refractory B-lineage leukemia and lymphoma. Anti-B4-bR was given as two 7-day continuous infusions separated by 7 days. Twenty patients were enrolled and 19 received the drug. Two dosage levels (30 and 40 g/kg per day) were evaluated. Forty micrograms per kilogram per day was the maximally tolerated dose. Dose-limiting toxicity was capillary leak syndrome. Grade 3 reversible elevation in transaminases was also encountered. Human antimouse antibodies or human antiricin antibodies were detected in five patients. No complete remissions or partial remissions were seen.
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. In most cases of childhood ALL, the malignant cell is derived from cells of B-cell origin and expresses the CD19 antigen (1) . A novel immunotoxin, anti-B4-blocked ricin (anti-B4-bR), combines a monoclonal antibody reactive with CD19 and blocked ricin (2) . Blocked ricin is a potent protein toxin that has been blocked by attaching affinity ligands to the galactose binding sites that mediate nonspecific binding. The anti-CD19 component of this immunotoxin allows it to deliver the ricin to cells that express the CD19 antigen. The blocked galactose binding sites of the ricin component prevent the nonspecific binding to cell surfaces that occurs with nonblocked ricin. Therefore, this immunotoxin is highly and selectively cytotoxic to all cells that express CD19. Its activity and toxicity in children with malignancies that express CD19 was of interest.
The starting dose and administration schedule for this trial were derived from results of previous trials of anti-B4-bR in adults. In the initial adult trial, anti-B4-bR was administered as a 1-hour intravenous bolus infusion for 5 days, and a maximally tolerated dose (MTD) of 50 g/kg per day was established (3) . Reversible grade 3 elevations in hepatic transaminases were the dose-limiting toxicities (DLTs) encountered. Minor toxicities included transient hypoalbuminemia, thrombocytopenia, and fever.
A subsequent phase I trial using a 7-day continuous infusion of anti-B4-bR also determined 50 g/kg per day to be the MTD (4) . In this trial, grade 4 elevation of hepatic transaminases and grade 4 thrombocytopenia were encountered. Additional adverse reactions included fever, nausea, headache, myalgia, hypoalbuminemia, dyspnea, edema, and capillary leak syndrome. A subsequent study using the same treatment schedule in patients in complete remission after autologous bone marrow transplant for non-Hodgkin lymphoma determined the MTD to be 40 g/kg per day. Dose-limiting toxicities were grade 4 thrombocytopenia and elevation of hepatic transaminases. Mild capillary leak syndrome also was encountered. Patients were eligible to receive a second course in 28 days. Seven of 12 patients studied developed human antiricin antibodies (HARA), human antimouse antibodies (HAMA), or both and therefore were ineligible for a second course. Antibodies developed 14 to 38 days from the start of treatment (i.e., from the initial day of therapy).
Development of HAMA and HARA after a course of therapy limits the potential usefulness of this agent. Treating patients with second courses of therapy after a 7-day rest would correspond to a time before most patients in the adult study had developed antibodies. We hypothesized that this schedule might allow patients to receive a higher cumulative dosage. This phase I pediatric trial was to determine an MTD of this agent in children with B-lineage ALL and non-Hodgkin lymphoma and to test the hypothesis that starting a second infusion at day 14 would allow more drug to be administered, bypassing the development of HAMA and HARA.
METHODS

Anti-B4-bR
Anti-B4-bR was manufactured and supplied by ImmunoGen, Inc. (Norwood, MA), as described (2, 5, 6) . Anti-B4-bR was formulated as a sterile injectable solution containing 100 g/mL anti-B4-bR dissolved in phosphate-buffered saline, pH 7.3, with 1 mg/mL (or 0.7 mg/mL) human serum albumin added as a carrier. Anti-B4-bR was stored at 2°to 8°C before administration.
Pharmacology
Blood samples were obtained for determination of serum concentrations of anti-B4-bR just before the immunotoxin infusion and on the final day of immunotoxin infusion (day 7). Anti-B4-bR concentration in serum was determined by using two independent enzyme-linked immunosorbent assay (ELISA) methods. The two ELISAs were sandwich assays in which the anti-B4-bR conjugate was captured on plates coated with sheep antimouse IgG (Fc specific) and then assayed with either goat antimouse IgG conjugated to alkaline phosphatase or rabbit antiricin Ig followed by goat antirabbit Ig conjugated to alkaline phosphatase. A signal amplification method (Bethesda Research Laboratories, Bethesda, MD) was used, allowing the use of highly diluted serum samples and reducing the nonspecific background signals. Because of component modification, serum drug concentrations of anti-B4-bR for three patients were assayed using goat antimouse IgG as the capture antibody rather than sheep antimouse IgG.
Antibody Detection
Samples for HAMA and HARA were to be obtained on days 12, 28, and 42 if the patient received the second 7-day infusion (day 0 ‫ס‬ the first day of the infusion). They were measured by established ELISA techniques that take advantage of the multivalency of the Ig molecules. The antigens (anti-B4 or blocked ricin) were coated on plates to capture the specific human antiserum. Biotinylated antigen was then captured by the bound human antiserum and assayed with streptavidin conjugated to horseradish peroxidase. In both assays, the antigens were used in excess, and the final signals recorded were directly proportional to the amount of absorbed specific human antibody. The HAMA reading was considered positive if the value was at least 0.468 g/mL, which represents the serum dilution multiplied by the lowest detectable concentration on the standard curve. The HARA reading was considered positive if the signal Å410 of the sample was at least 20% above the patient's baseline measurement. Because of a new instrument's specifications, serum samples assayed for HARA after December 2, 1993, were measured at an absorbancy of Å405.
Patient Selection
Patients entered on the CCG-0917 protocol were required to be younger than 21 years of age at initial diagnosis and to have histologic verification of B-lineage leukemia or lymphoma that expressed CD19. Patients with lymphoma were required to have measurable disease. Patients with ALL were eligible if there was evidence of overt disease or if there was evidence of recurrent disease by cytogenetic studies or polymerase chain reaction amplification of a unique immunoglobulin heavy chain region. Patients were ineligible if they had received prior therapy with murine monoclonal antibodies. Patients were required to have a performance status of 0, 1, or 2 and a life expectancy of at least 2 months.
Before study entry, patients must have been fully re-covered from the toxic effects of any prior therapy. A period of at least 2 weeks was to have elapsed since the last dose of chemotherapy (4 weeks in the case of nitrosourea-containing therapy). Patients with lymphoma and no bone marrow involvement were required to have an absolute neutrophil count of at least 1,500 and a platelet count of at least 100,000. Adequate organ function (renal: creatinine Յ1.5 times the upper limit of normal and blood urea nitrogen <25 mg/mL; hepatic: bilirubin Յ1.5 times the upper limit of normal and AST and ALT Յ2.5 times the upper limit of normal) was required. Patients were documented to be HIV negative. All patients or their parents or legal guardians were required to sign a written informed consent, and all institutional, Food & Drug Administration, and National Cancer Institute requirements for human studies were to be met. Patients were required to have a central line in place before administration of anti-B4-bR.
Study Design
A course of therapy consisted of a 7-day continuous infusion, a 7-day rest, and a second 7-day continuous infusion. Patients were not treated with the second 7-day infusion if they developed HAMA or HARA after the first 7-day infusion. Patients were eligible to receive up to four 7-day continuous infusions of anti-B4-bR if they did not develop HAMA or HARA, progressive disease, or DLT.
The initial dosage evaluated was 30 g/kg per day. The dosages scheduled were to be escalated in increments of 10 g/kg per day. Three patients were to be entered at each dosage level. If two patients experienced DLT, the level exceeded the MTD. If one patient of the three experienced DLT, an additional three patients were to be studied at that level. If none of the patients in the expanded cohort experienced DLT, that dosage level was considered the MTD. If two or more patients in the expanded cohort experienced DLT, the previous dosage level was considered the MTD.
Definition of Response
For patients with leukemia, a complete remission was defined as attainment of M1 bone marrow status (Յ5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (absolute neutrophil count Ն1,000/mm 3 and platelet count Ն100,000/mm 3 ), persisting for 4 weeks. A partial remission was defined as a complete disappearance of circulating blasts and achievement of M2 marrow status (5-25% blast cells), with recovery of peripheral counts (absolute neutrophil count Ն1,000/mm 3 and platelet count Ն100,000/mm 3 ), persisting for 4 weeks. For patients with lymphoma, a complete response was defined as complete disappearance of all known disease for at least 4 weeks. Complete response was dated from the time all lesions disappeared. A partial response was defined as a reduction of at least 50% in the size of all measurable tumors, as quantitated by the sum of the products of the largest diameters of measurable lesions for at least 4 weeks. Partial response was dated from the time of first observation. In addition, there could be no appearance of new lesions or progression of any lesion.
Definition of Toxicity
Toxicity evaluation (Children's Cancer Group toxicity criteria based on National Cancer Institute Common Toxicity Criteria) for the purpose of determining the MTD was based on nonhematologic toxicity observed. Dose-limiting toxicity was considered to be any grade 3 nonhematologic toxicity that did not return to grade 2 before initiation of the next cycle of therapy, or grade 4 nonhematologic toxicity occurring at any time. The treating physician was required to assess the degree of relatedness of the toxicity to treatment as unrelated, possibly related, probably related, or definitely related. Toxicities considered unrelated to therapy were not considered when assessing DLT.
Statistical Methods
Survival was measured from study entry until death or last follow-up. Patients alive at last contact were considered censored; otherwise, an event was considered to have occurred. The survivor function was estimated by the Kaplan-Meier method (7) .
RESULTS
A total of 20 patients were entered from 10 Children's Cancer Group phase I institutions between June 1992 and July 1996, including 19 patients with ALL and one with non-Hodgkin lymphoma. The demographics of these patients are given in Table 1 . Therapy, antibody detection, and toxicity are summarized in Table 2 . Seven patients were entered at the dosage level of 30 g/kg per day. One did not receive the B4-blocked ricin because the patient developed central nervous system leukemia and meningitic symptoms. Three patients finished two cycles of therapy. Thirteen patients were entered at the dosage level of 40 g/kg per day. Five patients completed at least two cycles of treatment, including one patient who developed DLT in the middle of the second cycle. One patient finished a third cycle. Accrual was slow and the study was closed without the final patient being enrolled. Twelve patients did not finish at least two cycles of therapy. Two patients were removed because an initial evaluation indicated they had developed HARA. After the study closed, review of the original assays indicated these patients did not show HARA. An additional nine patients developed progressive disease before cycle 2.
Antibody Development
All six patients who received 30 g/kg per day were assessed for HAMA and HARA. Three patients expressed HARA after the 7-day continuous infusion in the second cycle. Three patients received only one cycle of therapy. None developed HARA. One patient developed HAMA at the end of the second cycle of treatment (day 26), 5 days after showing HARA. The other five patients treated at this level did not show HAMA.
Twelve of the 13 patients who received 40 g/kg per day were assessed for HAMA and HARA. Two patients developed HAMA and HARA after the second cycle of therapy. The remaining 10 patients received therapy for one cycle (n ‫ס‬ 7), two cycles (n ‫ס‬ 2), or three cycles (n ‫ס‬ 1). None developed HAMA or HARA throughout their therapy.
Toxicity
At the dosage level of 30 g/kg per day, the three patients who finished two cycles of treatment are considered completely evaluable for DLT of toxicity. One patient had grade 3 elevation in AST (SGOT) during the second cycle, but this did not meet the protocol definition of DLT. A second patient experienced grade 3 nausea and vomiting possibly related to therapy in cycle two.
At the dosage level of 40 g/kg per day, the five patients who finished at least two cycles of treatment are considered evaluable for toxicity. One patient developed disseminated intravascular coagulation and bleeding possibly related to the agent. Two episodes of grade 3 capillary leak syndrome were observed during cycles 1 and 2, respectively, for one patient who was treated at this level. DLT was not observed on the other four evaluable patients. Therefore, the dosage level of 40 g/kg per day was considered the MTD.
Pharmacology
Sixteen patients had anti-B4-bR levels measured in their serum. Fifteen of the 16 had an undetectable level before the start of therapy. Thirteen patients had detectable levels on day 7 of infusion in cycle 1 (median 23 ng/mL [range 7-497]). One patient had a detectable drug level at the beginning of therapy (13 ng/mL), indicating nonspecific binding within the drug concentration assay. This patient reached the highest level (497 ng/mL) among all patients on day 7.
On day 21 after the start of treatment, four patients were assessed for drug level. The agent was not detected in three patients and was 23 ng/mL in the fourth. One patient had a drug level of 6 ng/mL on day 26 after starting treatment.
Survival
The medial survival of the 19 patients who received at least one dose of protocol therapy was 40 days.
Antitumor Activity
No patient achieved complete or partial responses as defined in the protocol. Five of eight patients had reductions in the percentage of blasts in their bone marrow on day 14. Two of these five had reductions of at least 50%; the bone marrow blast percentage changed from 92% at study entry to 30% in one patient and from 5% to 0% in the other patient.
DISCUSSION
Several clinical trials of anti-B4-bR in adults have been completed and reported (3) (4) (5) . This agent is of interest in pediatrics because B-lineage ALL is the most common type of leukemia seen in children (1) . CD19, the antigen recognized by anti-B4-bR, is expressed in virtually every case of B-lineage leukemia. Although current therapy for this disease is extremely successful, there remains a subset of patients who eventually suffer relapses (1) . In many instances, relapse occurs years after the initial remission, presumably after the leukemia has been in a prolonged quiescent phase. An agent that is active in nondividing cells during the period of quiescence may be a particularly effective approach for these patients. The MTD of anti-B4-bR had been determined to be 40 g/kg per day when given as a continuous infusion over 7 days to adults in complete remission after bone marrow transplantation (5) . In the initial design of this study, a subsequent 7-day infusion was to be given on day 28. Many patients were unable to receive the second course of drug because of the development of HAMA and HARA. We hypothesized that starting the second cycle after a 7-day rest would allow additional drug to be administered before the development of HAMA and HARA. Thus, we undertook this phase I trial in children with ALL and non-Hodgkin lymphoma that expressed CD19 to evaluate this schedule.
The capillary leak syndrome was considered doselimiting in this study. This is in contrast to adult studies that administered the drug as a 7-day continuous infusion. There, mild capillary leak syndrome was seen, but elevated transaminase levels were the DLT. In this study, reversible elevations in transaminase levels were seen but were not dose-limiting. Thrombocytopenia, which was seen frequently in the adult studies, could not be evaluated in this study because 19 of the 20 patients enrolled had ALL in relapse.
We were particularly interested in determining whether the schedule tested would allow administration of subsequent cycles of the drug. No patients developed antibody after the first cycle. Five of the 18 patients tested ultimately developed HARA, and 3 developed HAMA. However, the major factor that prevented the second cycle of therapy was progression of disease. This is not surprising because patients enrolled in this study gener- ally had advanced, rapidly progressive disease refractory to therapy. In summary, this agent was well tolerated for 7 days in 16 of 19 patients who began treatment. Subsequent treatment of 7 more days beginning on day 15 was limited primarily by progressive disease rather than toxicity or HAMA or HARA production. The decrease in the number of marrow blasts on day 14 suggests some potential clinical activity. These results indicate that further testing of this drug in childhood ALL may be warranted in highrisk patients with minimal tumor burden. In particular, patients who have had a relapse and achieved a second or subsequent remission could receive anti-B4-bR at the 40-g/m 2 dose for one course of therapy.
